Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ZONTIVITY

VORAPAXAR SULFATE

Standard Dose
EQ 2.08MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ZONTIVITY is listed in Drugs@FDA under application 204886 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient VORAPAXAR SULFATE Form and strength TABLET;ORAL - EQ 2.08MG BASE Sponsor KEY THERAP Submission history Latest submission status date: 2019-11-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZONTIVITY is listed in Drugs@FDA under application 204886 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient VORAPAXAR SULFATE Form and strength TABLET;ORAL - EQ 2.08MG BASE Sponsor KEY THERAP Submission history Latest submission status date: 2019-11-07 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.